MBX Biosciences, Inc. 8K

MBX Biosciences reported Q2 2026 results, advanced its endocrine and obesity pipeline including a Phase 3 trial for canvuparatide and new obesity candidates, strengthened its cash position, and announced CEO and CFO changes.

On August 6, 2026, MBX Biosciences, Inc. reported its financial results for the quarter ended June 30, 2026 and provided corporate updates, including sustained one-year Phase 2 and open-label extension data for once-weekly canvuparatide in chronic hypoparathyroidism and commencement of recruitment for its global Phase 3 pivotal oPTimize trial, encouraging initial Phase 1 multiple-ascending-dose data for obesity candidate MBX 4291 supporting the potential for once-monthly dosing, nomination of two additional preclinical obesity candidates (MBX 6180 and MBX 5765), disclosure of cash and investments of $418.6 million expected to fund operations into 2029, and executive leadership changes appointing Executive Chairman Steve Hoerter as Chairman and Chief Executive Officer and John Smither as Chief Financial Officer.

Filing Facts

CIK

1776111

Ticker

MBX

Form

8K

Source Type

fda

Accession

0001193125-26-336841

Alert Tier

6